An AACR Special Conference on

Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications

October 3-6, 2013 • The Manchester Grand Hyatt, San Diego, CA

Thursday, October 3

6:30 p.m.-8:00p.m. Welcome and Opening Keynote Talks

Session Co-Chairpersons: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Jeffrey M. Rosen, Baylor

College of Medicine, Houston, TX

Douglas B and C

6:30 p.m.-7:15 p.m. Breast cancer genomics: Implications for individuals and

populations

Charles M. Perou, University of North Carolina, Chapel Hill, NC

7:15 p.m.-8:00 p.m. **Tumor plasticity and reactive stroma in breast cancer**

metastasis

Yibin Kang, Princeton University, Princeton, NJ

8:00 p.m.-9:30 p.m. Opening Reception

Douglas D

Friday, October 4

7:30 a.m.-8:30 a.m. Continental Breakfast

Douglas BC Foyer

8:30 a.m.-10:30 a.m. Session 1: Genomics/Epigenomics/"Omics"

Session Chairperson: Charles M. Perou, University of North

Carolina, Chapel Hill, NC

Douglas B and C

8:30 a.m.-9:00 a.m. Clonal evolution and breast cancer subtypes

Samuel Aparicio, BC Cancer Research Center, Vancouver, BC,

Canada

9:00 a.m.-9:30 a.m. **Genomic studies of breast cancer progression**

Elaine R. Mardis, Washington University School of Medicine, St.

Louis, MO

9:30 a.m.-10:00 a.m. Understanding estrogen receptor transcription in breast

cancer

Jason S. Carroll, Cancer Research UK Cambridge Research

Institute, Cambridge, United Kingdom

10:00 a.m.-10:30 a.m. **Protein pathway activation mapping for personalized breast**

cancer therapy

Emanuel F. Petricoin, III, George Mason University, Manassas, VA

10:30 a.m.-11:00 a.m. Break

Douglas Foyer East

11:00 a.m.-12:45 p.m. **Session 2: Breast Cancer Models** Session Chairperson: Alana L. Welm, Huntsman Cancer Institute, Salt Lake City, UT Douglas B and C 11:00 a.m.-11:30 a.m. Breast tumor grafts as preclinical models for anti-metastasis Alana L. Welm 11:30 a.m.-12:00 p.m. Studying therapy response and resistance in mouse models of breast cancer Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands 12:00 p.m.-12:30 p.m. Targeting tumor-initiating cells in xenograft models of human breast cancer Michael T. Lewis, Baylor College of Medicine Cancer Center, Houston, TX Loss of the hippo pathway scaffold "Kibra" in a mouse model 12:30 p.m.-12:45 p.m. of human claudin-low breast cancer* Jennifer F. Knight, McGill University Goodman Cancer Research Centre, Montreal, QC, Canada Genomic rearrangements and promoter demethylation drive 12:45 p.m.-1:00 p.m. therapy resistance in patient-derived xenograft models of **BRCA1-deficient breast cancer*** Petra ter Brugge, Netherlands Cancer Institute, Amsterdam, The Netherlands 1:00 p.m.-3:30 p.m. Poster Session A/Lunch Douglas D/Douglas D Foyer

3:45 p.m5:45 p.m.	Session 3: Stem Cells/Mammary Lineage Tracing Session Chairperson: Jane E. Visvader, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia Douglas B and C
3:45 p.m4:15 p.m.	Using lineage tracing and clonal analysis to unravel mammary gland expansion and cancer initiation Alexandra Van Keymeülen, Université Libre de Bruxelles, Brussels, Belgium
4:15 p.m4:45 p.m.	Dissecting cancer through the lens of development Geoffrey M. Wahl, The Salk Institute, La Jolla, CA
4:45 p.m5:15 p.m.	Mammary epithelial subtypes and their implications for breast cancer Jane E. Visvader
5:15 p.m5:45 p.m.	Wnt and Fgf signaling in mammary stem cells and breast cancer Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX

Saturday, October 5

7:30 a.m.-8:30 a.m. Continental Breakfast

Douglas BC Foyer

8:30 a.m.-10:30 a.m. Session 4: Tumor Dormancy and Metastasis

Session Chairperson: Lewis A. Chodosh, University of

Pennsylvania, Philadelphia, PA

Douglas B and C

8:30 a.m.-9:00 a.m. Assembly and function of the tumor microenvironment of

metastasis in breast tumors

John S. Condeelis, Sr., Albert Einstein College of Medicine, Bronx,

NY

9:00 a.m.-9:30 a.m. Biology and clinical implications of circulating tumor cells

and bone marrow micrometastasis

Klaus Pantel, University Medical Center, Hamburg, Germany

9:30 a.m.-10:00 a.m. **Mechanisms of breast cancer dormancy and recurrence**

Lewis A. Chodosh

10:00 a.m.-10:15 a.m. The role of syndecan-1 in breast cancer metastasis to the

brain*

Melvin Moore, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,

Chicago, IL

10:15 a.m.-10:30 a.m. The Six2 homeoprotein mediates breast cancer metastasis

via repressing E-cadherin*

Chu-An Wang, University of Colorado at Denver, Anschutz

Medical Campus, Aurora, CO

10:30 a.m.-11:00 a.m. Break

Douglas Foyer East

11:00 a.m12:30 p.m.	Session 5: Targeted Therapies I Session Chairperson: Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, MN Douglas B and C
11:00 a.m11:30 a.m.	Targeting downstream effectors of growth factor signaling Douglas Yee
11:30 a.m12:00 p.m.	Targeting the androgen receptor in multiple breast cancer subtypes Jennifer K. Richer, University of Colorado Anschutz Medical Campus, Aurora, CO
12:00 p.m12:30 p.m.	Exploiting DNA repair deficiencies in breast cancer using PARP inhibitors Andrew Tutt, King's College London, London, United Kingdom
12:30 p.m2:45 p.m.	Free Time/Lunch on Own
2:45 p.m4:45 p.m.	Session 6: Targeted Therapies II Session Chairperson: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN Douglas B and C
2:45 p.m3:15 p.m.	Harnessing mTOR and translational control for the clinic Robert J. Schneider, New York University School of Medicine, New York, NY
3:15 p.m3:45 p.m.	Translating genetic screens into new therapeutic strategies Thomas (Trey) F. Westbrook, Baylor College of Medicine, Houston, TX
3:45 p.m4:15 p.m.	Rationale and current status of development of PI3K/TOR pathway inhibitors Carlos L. Arteaga
4:15 p.m4:30 p.m.	P-REX1 creates a positive feedback loop to activate growth factor receptor/PI3K signaling Lloye M. Dillon, Geisel School of Medicine at Dartmouth, Lebanon, NH
4:30 p.m4:45 p.m.	Overcoming resistance to PI3K inhibitors in breast cancer: Results of a pooled shRNA screen and combinatorial drug screen Sadhna Vora, Massachusetts General Hospital, Boston, MA

4:45 p.m.-7:15 p.m. Dinner on Own

7:15 p.m.-9:45 p.m. Poster Session B/Reception

Douglas D/Douglas D Foyer

Sunday, October 6

7:30 a.m.-8:30 a.m. Continental Breakfast

Douglas BC Foyer

8:30 a.m.-9:30 a.m. Session 7: Hot Topics/Late-Breaking Research

Session Chairperson: Jeffrey M. Rosen, Baylor College of

Medicine, Houston, TX

Douglas B and C

8:30 a.m.-9:00 a.m. Molecular and clinical impact of APOBEC3B mutagenesis in

breast cancer

Reuben S. Harris, University of Minnesota, Minneapolis, MN

9:00 a.m.-9:15 a.m. Integrative functional genomics of breast cancer*

Richard Marcotte, Ontario Cancer Institute, Toronto, ON, Canada

9:15 a.m.-9:30 a.m. Plk2 regulates mitotic spindle orientation and mammary

gland development*

Elizabeth Villegas, Baylor College of Medicine, Houston, TX

9:30 a.m.-9:45 a.m. Break

Douglas Foyer East

9:45 a.m.-11:45 a.m. **Session 8: Tumor Microenvironment and Immunity** Session Chairperson: Zena Werb, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA Douglas B and C 9:45 a.m.-10:15 a.m. How tumors regulate their microenvironment in primary sites and metastasis Zena Werb 10:15 a.m.-10:45 a.m. Tissue tension engages developmental programs to promote tumor progression Valerie M. Weaver, University of California Medical Center, San Francisco, CA 10:45 a.m.-11:15 a.m. Stroma-targeted immunotherapy Stephen Gottschalk, Texas Children's Cancer and Hematology Centers, Houston, TX 11:15 a.m.-11:45 a.m. Immunomodulation of breast cancer Mary (Nora) L. Disis, University of Washington, Seattle, WA

11:45 a.m.-12:00 p.m. Closing Remarks and Departure Douglas B and C